Dr Lal Pathlabs Q1 FY26 Earnings Analysis

Published 5 Aug 2026 | Healthcare Services | Market Cap: ₹31.7K Cr

Price

1,887.1

Market Cap

₹31.7K Cr

P/E Ratio

56.3

Earnings Summary

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

📊 Revenue & Sales Performance

No information is provided regarding the same in the latest conference call.

📈 Profitability & Margins

No information is provided regarding the same in the latest conference call.

🏗️ Capital Expenditure Plans

No information is provided regarding the same in the latest conference call.

💰 Fundraising & Capital Structure

No information is provided regarding the same in the latest conference call.

📋 Order Book & Pipeline

No information is provided regarding the same in the latest conference call.

Key Metrics

Frequently Asked Questions

What were Dr Lal Pathlabs Q1 FY26 results?

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

What is Dr Lal Pathlabs share price analysis?

Dr Lal Pathlabs currently shows a neutral. The stock trades at a P/E of 56.3 with a market cap of ₹31,652. Investors should review the full earnings analysis for detailed insights.

Is Dr Lal Pathlabs planning capital expenditure?

No information is provided regarding the same in the latest conference call.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

Others in Healthcare Services this season

  • Vijaya Diagnostic Centre Ltd (Q1 FY26)

    Vijaya Diagnostic Centre Ltd Q1 FY26 quarterly results analysis. No information is provided regarding the same in the latest conference call. Market Cap ₹14,313

  • Metropolis Healthcare Ltd (Q1 FY26)

    Metropolis Healthcare Ltd Q1 FY26 quarterly results analysis. No information is provided regarding the same in the latest conference call. Market Cap ₹11,961, P

  • Healthcare Global Enterprises Ltd (Q1 FY26)

    Healthcare Global Enterprises Ltd Q1 FY26 quarterly results analysis. - FY '25 revenue grew 16% to INR 2,223 crores; Q4 revenue rose 18% YoY to INR 585 crores.

  • Thyrocare Technologies Ltd (Q1 FY26)

    Thyrocare Technologies Ltd Q1 FY26 quarterly results analysis. - Mid-teens revenue growth expected for FY '26, with cautious optimism due to a high current base